Paronychia and periungual pyogenic granuloma represent one of the most common and bothersome dermatologic toxicities observed with ErbB inhibitors. There is no standardized treatment, and management remains challenging. Moreover, conservative management with noninvasive treatment should be promoted for fragile patients in a metastatic setting. Over the last few years, the efficacy of topical blocking agents has been considered for managing cutaneous or mucosal pyogenic granulomas. Very recently, the use of topical propranolol or of timolol has been reported in several patients undergoing treatment with EGFR inhibitors and developing pyogenic granulomas of the nail. We performed a retrospective single-center review of patients with targeted therapy-related paronychia/periungual pyogenic granulomas who had been treated with topical timolol, either alone or in combination with other topical treatments. Nearly two thirds of patients showed at least a partial response after 1 month of therapy, and the use of a topical beta-blocker in our population was associated with a favorable safety profile. Finally, topical timolol may represent a promising treatment option for the management of cancer patients suffering from painful periungual lesions. Comparative clinical trials, however, are still needed.
Paronychia Pyogenic granuloma Timolol Beta blocker EGFR Nail
This is a preview of subscription content, log in to check access.
Compliance with ethical standards
Conflict of interest
Dr. Sibaud reports grants from Roche, grants from Novartis, grants from BMS, grants from Bayer, grants from Pierre Fabre, and outside the submitted work. Dr. Casassa has nothing to disclose. Mirella D’Andrea has nothing to disclose.
Robert C, Sibaud V, Mateus C, Verschoore M, Charles C, Lanoy E et al (2015) Nail toxicities induced by systemic anticancer treatments. Lancet Oncol 16:e181–e189CrossRefPubMedGoogle Scholar
Lacouture M, Sibaud V (2018) Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol 19:31–39CrossRefPubMedGoogle Scholar
Sibaud V, Dalenc F, Mourey L, Chevreau C (2011) Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors. Acta Derm Venereol 91:584–585CrossRefPubMedGoogle Scholar
Garden BC, Wu S, Lacouture ME (2012) The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 67:400–408CrossRefPubMedGoogle Scholar
Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G et al (2015) A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 372:735–746CrossRefPubMedGoogle Scholar
Chisholm KM, Chang KW, Truong MT, Kwok S, West RB, Heerema-McKenney AE (2012) β-Adrenergic receptor expression in vascular tumors. Mod Pathol 25:1446–1451CrossRefPubMedGoogle Scholar
Neri I, Baraldi C, Balestri R, Piraccini BM, Patrizi A (2018) Topical 1% propranolol ointment with occlusion in treatment of pyogenic granulomas: an open-label study in 22 children. Pediatr Dermatol 35:117–120CrossRefPubMedGoogle Scholar
Knöpfel N, Escudero-Góngora MDM, Bauzà A, Martín-Santiago A (2016) Timolol for the treatment of pyogenic granuloma (PG) in children. J Am Acad Dermatol 75:e105–e106CrossRefPubMedGoogle Scholar
Wine Lee L, Goff KL, Lam JM, Low DW, Yan AC, Castelo-Soccio L (2014) Treatment of pediatric pyogenic granulomas using β-adrenergic receptor antagonists. Pediatr Dermatol 31:203–207CrossRefPubMedGoogle Scholar
Baek YS, Kwon SH, Jeon J (2018) Combination of ligation and timolol before surgical excision of pyogenic granuloma. J Am Acad Dermatol 78:e141–e142CrossRefPubMedGoogle Scholar
Gupta D, Singh N, Thappa DM (2016) Is timolol an effective treatment for pyogenic granuloma? Int J Dermatol 55:592–595CrossRefPubMedGoogle Scholar
Piraccini BM, Alessandrini A, Dika E, Starace M, Patrizi A, Neri I (2016) Topical propranolol 1% cream for pyogenic granulomas of the nail: open-label study in 10 patients. J Eur Acad Dermatol Venereol 30:901–902CrossRefPubMedGoogle Scholar
Cubiró X, Planas-Ciudad S, Garcia-Muret MP, Puig L (2018) Topical timolol for paronychia and pseudopyogenic granuloma in patients treated with epidermal growth factor receptor inhibitors and capecitabine. JAMA Dermatol 154:99–100CrossRefPubMedGoogle Scholar
Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB et al (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19:1079–1095CrossRefPubMedGoogle Scholar
Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A (2015) Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol 72:203–218CrossRefPubMedGoogle Scholar
Capriotti K, Capriotti J, Pelletier J, Stewart K (2017) Chemotherapy-associated paronychia treated with 2% povidone-iodine: a series of cases. Cancer Manag Res 9:225–228CrossRefPubMedGoogle Scholar
Yen CF, Lee YY (2018) Nail braces for severe paronychia induced by epidermal growth factor receptor inhibitors: an alternative to nail extraction. J Am Acad Dermatol 78:e89–e90CrossRefPubMedGoogle Scholar